Tilray Brands (TLRY) has been getting high lately. And that’s not at all a pot pun. You might say I “rescheduled” my priorities in shifting research to this hot company. Because that’s the key word that could eventually take TLRY to a two-digit stock price for the first time since the end of 2021.
Rescheduling is what they call it when a substance like cannabis, the core of TLRY’s business, changes classification. The U.S. Drug Enforcement Administration (DEA) is strongly considering moving cannabis from Schedule I to Schedule III. That means instead of being considered in the same class as heroin, it would be on par with things like Tylenol with codeine, and anabolic steroids.
